164 related articles for article (PubMed ID: 1087913)
1. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
Takahashi S; Takahashi R; Masumura I; Miike A
Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
[TBL] [Abstract][Full Text] [Related]
2. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
Takahashi S; Takahashi R; Masumura I; Miike A
Folia Psychiatr Neurol Jpn; 1976; 30(4):463-73. PubMed ID: 1088138
[TBL] [Abstract][Full Text] [Related]
3. The indoleamine hypothesis of depression: an overview and pilot study.
Zarcone VP; Berger PA; Brodie KH; Sack R; Barchas JD
Dis Nerv Syst; 1977 Aug; 38(8):646-53. PubMed ID: 328245
[TBL] [Abstract][Full Text] [Related]
4. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression.
Amamoto T; Sarai K
Hiroshima J Med Sci; 1976 Sep; 25(2-3):135-40. PubMed ID: 1088369
[No Abstract] [Full Text] [Related]
5. Reduction of blood platelet serotonin levels in manic and depressed patients.
Takahashi S
Folia Psychiatr Neurol Jpn; 1976; 30(4):476-86. PubMed ID: 1087914
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls.
Croonenberghs J; Verkerk R; Scharpe S; Deboutte D; Maes M
Life Sci; 2005 Mar; 76(19):2171-83. PubMed ID: 15733932
[TBL] [Abstract][Full Text] [Related]
7. The Harold E. Himwich Memorial Lecture. Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders.
Praag HM
Biol Psychiatry; 1977 Feb; 12(1):101-31. PubMed ID: 300032
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of 5-hydroxyindole derivates after administration of L-5-hydroxytryptophan ethyl ester.
Korf J; Sebens JB; Venema K; van Praag HM
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):171-82. PubMed ID: 968174
[TBL] [Abstract][Full Text] [Related]
9. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
Thal LJ; Sharpless NS; Wolfson L; Katzman R
Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054
[TBL] [Abstract][Full Text] [Related]
10. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
Joy T; Walsh G; Tokmakejian S; Van Uum SH
Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781
[TBL] [Abstract][Full Text] [Related]
11. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects.
Byerley WF; Judd LL; Reimherr FW; Grosser BI
J Clin Psychopharmacol; 1987 Jun; 7(3):127-37. PubMed ID: 3298325
[TBL] [Abstract][Full Text] [Related]
12. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and myoclonus.
Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients.
Mitani H; Shirayama Y; Yamada T; Kawahara R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):531-4. PubMed ID: 16414168
[TBL] [Abstract][Full Text] [Related]
15. L-5HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients.
Kaneko M; Kumashiro H; Takahashi Y; Hoshino Y
Neuropsychobiology; 1979; 5(4):232-40. PubMed ID: 312470
[TBL] [Abstract][Full Text] [Related]
16. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.
Turner EH; Loftis JM; Blackwell AD
Pharmacol Ther; 2006 Mar; 109(3):325-38. PubMed ID: 16023217
[TBL] [Abstract][Full Text] [Related]
17. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder.
Hou C; Jia F; Liu Y; Li L
Brain Res; 2006 Jun; 1095(1):154-8. PubMed ID: 16713589
[TBL] [Abstract][Full Text] [Related]
18. Fluctuation of 5-hydroxy-indole compounds in the urine of migrainous patients.
Deanović Z; Iskrić S; Dupelj M
Biomedicine; 1975 Nov; 23(9):346-9. PubMed ID: 1231931
[TBL] [Abstract][Full Text] [Related]
19. Brain and peripheral metabolism of 5-hydroxytryptophan-14C following peripheral decarboxylase inhibition.
Warsh JJ; Stancer HC
J Pharmacol Exp Ther; 1976 Jun; 197(3):545-55. PubMed ID: 1084420
[TBL] [Abstract][Full Text] [Related]
20. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
Magnussen I; Jensen TS; Rand JH; Van Woert MH
Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
